DDIT4L抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P01280(DDIT4L Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

The DNA Damage Inducible Transcript 4-Like (DDIT4L) protein, also known as REDD2 or RTP801L, is a stress-responsive regulator implicated in cellular processes such as apoptosis, autophagy, and metabolism. It belongs to the REDD1 protein family and shares structural homology with DDIT4/REDD1. DDIT4L is primarily induced under hypoxic, oxidative, or DNA-damaging conditions, where it acts as a key modulator of the mTOR (mammalian target of rapamycin) signaling pathway. By inhibiting mTORC1 activity, DDIT4L suppresses cell growth and promotes stress adaptation, linking cellular energy status to metabolic regulation. Dysregulation of DDIT4L has been associated with cancer, neurodegenerative disorders, and metabolic diseases, highlighting its therapeutic relevance.

DDIT4L antibodies are immunological tools developed to detect and quantify endogenous DDIT4L protein expression in research applications. These antibodies, often raised in rabbits or mice using recombinant DDIT4L antigens, enable the study of its expression patterns, subcellular localization, and interaction partners through techniques like Western blotting, immunohistochemistry, and immunofluorescence. Specificity validation via knockout controls is critical due to potential cross-reactivity with homologous proteins like DDIT4/REDD1. Researchers utilize DDIT4L antibodies to investigate its role in stress responses, tumor progression (where it may act as a tumor suppressor or promoter depending on context), and metabolic disorders. Recent studies also explore its involvement in aging-related processes and immune regulation, making these antibodies valuable for both basic research and preclinical investigations.